Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)

Exclusion Criteria

• •Participants who meet any of the following criteria will be excluded from participation in the study:
• •Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose \>0.5 mg/kg/day or equivalent).
• •Therapy with antithymocyte globulin, alemtuzumab (Campath-1H), or other immunosuppressive T cell-targeted monoclonal antibodies ≤28 days before randomization.
• •Evidence of active Grade \>2 acute graft versus host disease (GVHD).
• •Uncontrolled or progressive bacterial or fungal infections.
• •Uncontrolled or progressive viral infections not targeted by posoleucel (ALVR105).
• •Uncontrolled or progressive EBV-associated post-transplant lymphoproliferative disorder.
• •Known or presumed pneumonia secondary to any organism that is not considered to be well-controlled by antimicrobial therapy.
• •Pregnant or lactating or planning to become pregnant.